In addition, for increased survival times and an improved performance status, studies at the molecular biological level, including resistance mechanisms and targeted therapy (for example, antiangiogenic biologicals or trastuzumab in patients positive for HER-2), are likely to be significant issues in the future.
← all excerpts
Paclitaxel combined with capecitabine as first-line chemotherapy for advanced or recurrent gastric cancer.
1
—
—